Health Condition 1: null- Chronic plaque psorisis
Conditions
Interventions
Intervention1: isotretinoin: isotretinoin 30 daily will be used as intervention
Control Intervention1: Methtrexate: Methotrexate 15mg once a week will be used as comparator agent
Sponsors
None
Dr Abhinav
Dr Karaninder S Mehta
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients having >10% of body surface area involved by psoriasis and no psoriatic arthritis. 2. Patients having moderate-to-severe chronic plaque psoriasis (defined by a score of at least 6 on the Psoriasis Area-and-Severity Index (PASI). 3. Patients not on any form of systemic antipsoriatic treatment for at least 4 weeks and/or topical treatment for at least 2 weeks prior to the initiation of therapy.
Exclusion criteria
Exclusion criteria: 1. Patients less than 18 years of age. 2. Pregnant and / or lactating females. 3. Patients noncompliant with an effective regimen of contraception. 4. Patients having hepatic or renal impairment, deranged lipid profile, hematologic impairment, any acute infection requiring antimicrobial therapy, uncontrolled hypertension or diabetes mellitus, with BMI >30 or known psychiatric illness. 5. Patients having a history of cancer, including skin cancer or hematologic, cerebral or pulmonary neoplasia. 6. Patients who were alcoholic or had a long history of alcohol intake.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The reduction in PASI score was the primary outcome measure.Timepoint: At 2 weeks, 4 weeks, 8 weeks and at 12 weeks follow up. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug associated adverse effectsTimepoint: At 2 weeks, 4 weeks, 8 weeks and at 12 weeks follow up or as and when these are reported by the patients. | — |
Countries
India
Contacts
Public ContactVikram Mahajan
Dr. R. P. Govt Medical College Kangra (Tanda)
Outcome results
None listed